Literature DB >> 8787907

In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.

L Welsh1, C Gaydos, T C Quinn.   

Abstract

Thirteen strains of Chlamydia pneumoniae were evaluated for their in vitro susceptibilities to azithromycin, clarithromycin, erythromycin, and tetracycline. The MIC ranges were 0.125 to 0.5 micrograms/ml for azithromycin, 0.031 to 1.0 micrograms/ml for clarithromycin, 0.125 to 1.0 micrograms/ml for erythromycin, and 0.25 to 1.0 micrograms/ml for tetracycline. The ranges for the minimal lethal concentrations were 0.125 to 0.5 micrograms/ml for azithromycin, 0.031 to 1.0 micrograms/ml for clarithromycin, 0.125 to 1.0 micrograms/ml for erythromycin, and 0.25 to 1.0 micrograms/ml for tetracycline. Clarithromycin and azithromycin were the most active antibiotics against C. pneumoniae in vitro.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8787907      PMCID： PMC163084     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  L E Welsh; C A Gaydos; T C Quinn
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

Authors:  K Chirgwin; P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.

Authors:  M Walsh; E W Kappus; T C Quinn
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 4.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

5.  Relative resistance to erythromycin in Chlamydia trachomatis.

Authors:  A Mourad; R L Sweet; N Sugg; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  Community-acquired pneumonia: impact of immune status.

Authors:  L M Mundy; P G Auwaerter; D Oldach; M L Warner; A Burton; E Vance; C A Gaydos; J M Joseph; R Gopalan; R D Moore
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

Review 7.  New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety.

Authors:  K A Rodvold; S C Piscitelli
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

8.  Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia.

Authors:  P M Roblin; G Montalban; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections.

Authors:  J T Grayston; C C Kuo; S P Wang; J Altman
Journal:  N Engl J Med       Date:  1986-07-17       Impact factor: 91.245

10.  Azithromycin concentrations at the sites of pulmonary infection.

Authors:  D R Baldwin; R Wise; J M Andrews; J P Ashby; D Honeybourne
Journal:  Eur Respir J       Date:  1990-09       Impact factor: 16.671
View more
  8 in total

1.  Chlamydia pneumoniae resists antibiotics in lymphocytes.

Authors:  Hiroyuki Yamaguchi; Herman Friedman; Mayumi Yamamoto; Keigo Yasuda; Yoshimasa Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 2.  Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors:  H D Langtry; R N Brogden
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

3.  In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.

Authors:  H M Freidank; P Losch; H Vögele; M Wiedmann-Al-Ahmad
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome--a randomized study.

Authors:  S Schönwald; I Kuzman; K Oresković; V Burek; V Skerk; V Car; D Bozinović; J Culig; S Radosević
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

Review 5.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Azithromycin. A review of its use in paediatric infectious diseases.

Authors:  H D Langtry; J A Balfour
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

Review 7.  Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.

Authors:  George G Zhanel; Jenine Esquivel; Sheryl Zelenitsky; Courtney K Lawrence; Heather J Adam; Alyssa Golden; Rachel Hink; Liam Berry; Frank Schweizer; Michael A Zhanel; Denice Bay; Philippe R S Lagacé-Wiens; Andrew J Walkty; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

8.  Antibacterial activity of biosecur(®) citrus extract surface cleaner against Vibrio vulnificus.

Authors:  Jiemin Cormier; Ronson Scott; Marlene Janes
Journal:  Open Microbiol J       Date:  2013-11-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.